DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS FOR PRIMARYMEDIASTINAL LARGE B-CELL LYMPHOMA: A RETROSPECTIVESTUDY ON 86 PREVIOUSLY UNTREATED PATIENTS
(Abstract release date: 05/19/16)
EHA Library. Ilyasova I. 06/09/16; 134617; PB1717
Dr. Inga Ilyasova
Contributions
Contributions
Abstract
Abstract: PB1717
Type: Publication Only
Background
Primary mediastinal large B-cell lymphoma (PMBCL) arising from thymic medulla B cell, occurring more often in young females and characterized by a locally invasive anterior mediastinal bulky mass that often causes cough, dyspnea and a superior vena cava syndrome. Previous retrospective studies have suggested that it may respond better to more intensive chemotherapy regimens than to standard CHOP. The prognostic role of PET/CT scan and the feasibility of consolidation with radiotherapy (RT) on residual mediastinal mass still remain unclear.
Aims
To assess the impact of different immunochemotherapy regimens on survival outcomes in newly diagnosed patients with PMBCL.
Methods
We identified 86 pts with PMBCL treated in N.N. Blokhin Russian Cancer Research Center during last 10 years (2004-2014). The median age was 29 years (15-63), 56% were female, 62% had I/IIE stages, LDH elevated in 81% pts. Patients received three different regimens chemotherapy (CT): MACOP-B + R- 52 pts (group 1), R-CHOP -18 pts (group 2), R-EPOCH - 16 pts (group 3). After completion of CT, PET/CT scan was performed on 56 of 86 pts and in 20 of 56 (36%) it was abnormal. Radiation therapy to the mediastinum received 69 pts (80%).
Results
With a median follow 34 months, progression-free survival (PFS) was 80%, overall survival (OS) - 86%. There is no significant differences in PFS and OS depending on the CT regimens (p = 0.1). It should be noted that none of the 16 patients treated on EPOCH-R, had relapse or disease progression. 4-year PFS was 91% in patients who were PET negative before RT regardless of the CH regimens
Conclusion
Immunochemotherapy combined with local irradiation remains the standard treatment for PMBCL. Perhaps, more number of patients will be able to demonstrate significant benefit one chemotherapy regimens over the other and define the role of consolidation RT in patients with PET-negative mediastinal mass after standard chemoimmunotherapy.
Session topic: E-poster
Keyword(s): Lymphoma therapy, PET
Type: Publication Only
Background
Primary mediastinal large B-cell lymphoma (PMBCL) arising from thymic medulla B cell, occurring more often in young females and characterized by a locally invasive anterior mediastinal bulky mass that often causes cough, dyspnea and a superior vena cava syndrome. Previous retrospective studies have suggested that it may respond better to more intensive chemotherapy regimens than to standard CHOP. The prognostic role of PET/CT scan and the feasibility of consolidation with radiotherapy (RT) on residual mediastinal mass still remain unclear.
Aims
To assess the impact of different immunochemotherapy regimens on survival outcomes in newly diagnosed patients with PMBCL.
Methods
We identified 86 pts with PMBCL treated in N.N. Blokhin Russian Cancer Research Center during last 10 years (2004-2014). The median age was 29 years (15-63), 56% were female, 62% had I/IIE stages, LDH elevated in 81% pts. Patients received three different regimens chemotherapy (CT): MACOP-B + R- 52 pts (group 1), R-CHOP -18 pts (group 2), R-EPOCH - 16 pts (group 3). After completion of CT, PET/CT scan was performed on 56 of 86 pts and in 20 of 56 (36%) it was abnormal. Radiation therapy to the mediastinum received 69 pts (80%).
Results
With a median follow 34 months, progression-free survival (PFS) was 80%, overall survival (OS) - 86%. There is no significant differences in PFS and OS depending on the CT regimens (p = 0.1). It should be noted that none of the 16 patients treated on EPOCH-R, had relapse or disease progression. 4-year PFS was 91% in patients who were PET negative before RT regardless of the CH regimens
Conclusion
Immunochemotherapy combined with local irradiation remains the standard treatment for PMBCL. Perhaps, more number of patients will be able to demonstrate significant benefit one chemotherapy regimens over the other and define the role of consolidation RT in patients with PET-negative mediastinal mass after standard chemoimmunotherapy.
Session topic: E-poster
Keyword(s): Lymphoma therapy, PET
Abstract: PB1717
Type: Publication Only
Background
Primary mediastinal large B-cell lymphoma (PMBCL) arising from thymic medulla B cell, occurring more often in young females and characterized by a locally invasive anterior mediastinal bulky mass that often causes cough, dyspnea and a superior vena cava syndrome. Previous retrospective studies have suggested that it may respond better to more intensive chemotherapy regimens than to standard CHOP. The prognostic role of PET/CT scan and the feasibility of consolidation with radiotherapy (RT) on residual mediastinal mass still remain unclear.
Aims
To assess the impact of different immunochemotherapy regimens on survival outcomes in newly diagnosed patients with PMBCL.
Methods
We identified 86 pts with PMBCL treated in N.N. Blokhin Russian Cancer Research Center during last 10 years (2004-2014). The median age was 29 years (15-63), 56% were female, 62% had I/IIE stages, LDH elevated in 81% pts. Patients received three different regimens chemotherapy (CT): MACOP-B + R- 52 pts (group 1), R-CHOP -18 pts (group 2), R-EPOCH - 16 pts (group 3). After completion of CT, PET/CT scan was performed on 56 of 86 pts and in 20 of 56 (36%) it was abnormal. Radiation therapy to the mediastinum received 69 pts (80%).
Results
With a median follow 34 months, progression-free survival (PFS) was 80%, overall survival (OS) - 86%. There is no significant differences in PFS and OS depending on the CT regimens (p = 0.1). It should be noted that none of the 16 patients treated on EPOCH-R, had relapse or disease progression. 4-year PFS was 91% in patients who were PET negative before RT regardless of the CH regimens
Conclusion
Immunochemotherapy combined with local irradiation remains the standard treatment for PMBCL. Perhaps, more number of patients will be able to demonstrate significant benefit one chemotherapy regimens over the other and define the role of consolidation RT in patients with PET-negative mediastinal mass after standard chemoimmunotherapy.
Session topic: E-poster
Keyword(s): Lymphoma therapy, PET
Type: Publication Only
Background
Primary mediastinal large B-cell lymphoma (PMBCL) arising from thymic medulla B cell, occurring more often in young females and characterized by a locally invasive anterior mediastinal bulky mass that often causes cough, dyspnea and a superior vena cava syndrome. Previous retrospective studies have suggested that it may respond better to more intensive chemotherapy regimens than to standard CHOP. The prognostic role of PET/CT scan and the feasibility of consolidation with radiotherapy (RT) on residual mediastinal mass still remain unclear.
Aims
To assess the impact of different immunochemotherapy regimens on survival outcomes in newly diagnosed patients with PMBCL.
Methods
We identified 86 pts with PMBCL treated in N.N. Blokhin Russian Cancer Research Center during last 10 years (2004-2014). The median age was 29 years (15-63), 56% were female, 62% had I/IIE stages, LDH elevated in 81% pts. Patients received three different regimens chemotherapy (CT): MACOP-B + R- 52 pts (group 1), R-CHOP -18 pts (group 2), R-EPOCH - 16 pts (group 3). After completion of CT, PET/CT scan was performed on 56 of 86 pts and in 20 of 56 (36%) it was abnormal. Radiation therapy to the mediastinum received 69 pts (80%).
Results
With a median follow 34 months, progression-free survival (PFS) was 80%, overall survival (OS) - 86%. There is no significant differences in PFS and OS depending on the CT regimens (p = 0.1). It should be noted that none of the 16 patients treated on EPOCH-R, had relapse or disease progression. 4-year PFS was 91% in patients who were PET negative before RT regardless of the CH regimens
Conclusion
Immunochemotherapy combined with local irradiation remains the standard treatment for PMBCL. Perhaps, more number of patients will be able to demonstrate significant benefit one chemotherapy regimens over the other and define the role of consolidation RT in patients with PET-negative mediastinal mass after standard chemoimmunotherapy.
Session topic: E-poster
Keyword(s): Lymphoma therapy, PET
{{ help_message }}
{{filter}}